Safety Profile of Nivolumab Monotherapy: A Pooled Analysis of Patients With Advanced Melanoma.

By J. Weber, F. Hodi, J. Wolchok, S. Topalian, D. Schadendorf, J. Larkin, M. Sznol, Georgina V. Long, Hewei Li, I. Waxman and 2 more. Journal of Clinical Oncology, 2017

985 citations recorded by the source corpus.

Subfields: Molecular Biology, Oncology

View Paper: https://www.semanticscholar.org/paper/1b791bddef6ba146e238747dd838337d2e6e0bff

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Molecular Biology

1. J. Wolchok
2. C. Robert
3. M. Lacouture
4. J. Goldberg

In Oncology

1. J. Wolchok
2. C. Robert
3. K. Kerr
4. J. Haanen
5. J. Larkin
6. S. Peters
7. F. Carbonnel
8. M. Lacouture

Citations in the corpus

• Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline (2018, background): “After adjusting for differences in number of nivolumab doses received, baseline LDH, and tumor PD-L1 expression, one analysis found that the ORR was significantly better in patients who experienced irAEs of any grade compared with those who did not, with the greatest benefit seen in patients who rep”
• Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group (2017, background): “Some retrospective analyses suggest that use of corticosteroids for the management of irAEs is not associated with inferior results of therapy [31, 32] but, due Fig.”
• Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. (2018, background): “Importantly, so far there is no evidence that the clinical outcome of patients on ICPis is affected by the use of immunosuppressive agents for the management of immune-related toxicities [7, 18].”
• Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. (2017, background): “Importantly, so far there is no evidence that the clinical outcome of patients on ICPis is affected by the use of immunosuppressive agents for the management of immune-related toxicities [7, 18].”